Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Kite Pharma
Kite Pharma
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Biopharma Reporter
Wed, 04/7/21 - 07:13 pm
Kite Pharma
Yescarta
CAR-T
'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
Endpoints
Mon, 02/8/21 - 10:33 am
Kite Pharma
Gilead Sciences
clinical development
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
Fierce Biotech
Thu, 01/21/21 - 10:32 am
NexImmune
Gilead Sciences
Kite Pharma
IPOs
Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
Pharmaforum
Thu, 01/7/21 - 11:28 am
Kite Pharma
Gilead Sciences
Oxford BioTherapeutics
solid tumors
blood cancer
cell therapy
ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy
Fierce Pharma
Tue, 12/8/20 - 12:07 am
Gilead Sciences
Kite Pharma
Yescarta
diffuse large B-cell lymphoma
clinical trials
COVID-19 vaccine biotech Vaccitech nabs Pfizer, Kite vet as full-time CMO
Fierce Biotech
Tue, 10/20/20 - 10:42 am
Vaccitech
Pfizer
Kite Pharma
vaccines
AstraZeneca
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas
MedCity News
Tue, 09/8/20 - 10:40 am
Gilead Sciences
Yescarta
follicular lymphoma
marginal zone lymphoma
ASCO 2020
Kite Pharma
Kite, a Gilead Company, Looks to Expand Its Cell Therapy Maryland Operations
BioSpace
Mon, 08/10/20 - 10:55 pm
Kite Pharma
Gilead Sciences
Maryland
cell therapy
Gilead’s Kite gains some height after second CAR-T approval in US
Pharmaforum
Tue, 07/28/20 - 10:57 am
Gilead Sciences
Kite Pharma
CAR-T
Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy
MedCity News
Sat, 07/25/20 - 02:29 pm
Gilead Sciences
CAR-T
KTE-X19
Tecartus
FDA
Kite Pharma
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
Wed, 06/24/20 - 11:21 pm
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Fierce Biotech
Wed, 04/22/20 - 11:04 am
Gilead Sciences
Kite Pharma
oNKo-innate
CAR-T
natural killer cell therapies
FDA Speeds Up Examination of 5 Drugs with Priority Review
BioSpace
Thu, 02/13/20 - 12:24 am
FDA
priority review
capmatinib
Kite Pharma
KTE-X19
Eli Lilly
selpercatinib
GSK
belantamab mafodotin
Astex
C-DEC
Gilead closes in on second CAR-T approval in US
Pharmaforum
Tue, 02/11/20 - 10:30 am
FDA
Gilead Sciences
Kite Pharma
mantle cell lymphoma
CAR-T
FDA Grants Priority Review For Kite's KTE-X19 BLA
NASDAQ
Mon, 02/10/20 - 10:27 am
Gilead Sciences
Kite Pharma
KTE-X19
priority review
FDA
mantle cell lymphoma
Gilead CEO O'Day feels 'sense of urgency' on dealmaking as Kite writedowns add up
Fierce Pharma
Wed, 02/5/20 - 10:13 pm
Gilead Sciences
Kite Pharma
Daniel O'Day
Pharma CEOs
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Fri, 12/13/19 - 09:09 pm
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
Gilead's Kite files for FDA approval of second CAR-T therapy
Fierce Biotech
Thu, 12/12/19 - 11:27 am
Gilead Sciences
KTE-X19
mantle cell lymphoma
CAR-T
Kite Pharma
Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit
Stat
Thu, 07/11/19 - 05:18 pm
Christi Shaw
Kite Pharma
Gilead Sciences
cancer
Pharma CEOs
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »